Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.41 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.38 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.38 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.38 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.38 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.38 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23325452 | 0.80 | HPGD (0.50) | HPGDHRH3L3MBTL3L3MBTL1TDP1 | |
| SCHEMBL20209312 | 0.79 | HPGD (0.52) | HPGDHRH3L3MBTL3L3MBTL1TDP1 | |
| SCHEMBL63831 | 0.79 | P4HTM (0.56) | L3MBTL1TDP1 | |
| SCHEMBL9823266 | 0.79 | P4HTM (0.42) | SMN1; SMN2 | |
| SCHEMBL25732487 | 0.79 | L3MBTL1 (0.49) | HPGDHRH3L3MBTL3L3MBTL1TDP1 | |
| SCHEMBL30871624 | 0.76 | HDAC3 (0.41) | SMN1; SMN2 | |
| SCHEMBL6119180 | 0.76 | MAPK1 (0.53) | HPGDL3MBTL1SMN1; SMN2 | |
| SCHEMBL46306 | 0.72 | TDP1 (0.65) | HPGDHRH3L3MBTL3L3MBTL1TDP1 | |
| SCHEMBL30341672 | 0.72 | TDP1 (0.65) | HPGDHRH3L3MBTL3L3MBTL1TDP1 | |
| SCHEMBL23708084 | 0.72 | HRH3 (0.55) | HPGDHRH3L3MBTL3L3MBTL1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119161324-A | Methods and compounds for restoring mutant p53 function | 皮姆维制药公司 | 2024-12-20 | — | — | CN | disclosed |
| US-20220213062-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2022-07-07 | — | — | US | disclosed |
| US-11339141-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210002252-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2021-01-07 | — | — | US | disclosed |
| US-10640485-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190119249-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2019-04-25 | — | — | US | disclosed |
| EP-3416638-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2018-12-26 | — | — | EP | disclosed |
| US-10138219-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS (US) | 2018-11-27 | — | — | US | disclosed |
| US-20170240525-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2017-08-24 | — | — | US | disclosed |
| WO-2017143291-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240525-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | HPGD 905/4885HRH3 4589/4885L3MBTL3 188/4885 |
| US-11339141-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | HPGD 905/4885HRH3 4589/4885L3MBTL3 188/4885 |
| US-20220213062-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | HPGD 905/4885HRH3 4589/4885L3MBTL3 188/4885 |
| US-20190119249-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | HPGD 905/4885HRH3 4589/4885L3MBTL3 188/4885 |
| US-10640485-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | HPGD 905/4885HRH3 4589/4885L3MBTL3 188/4885 |
| US-20210002252-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | HPGD 905/4885HRH3 4589/4885L3MBTL3 188/4885 |
| US-10138219-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | HPGD 905/4885HRH3 4589/4885L3MBTL3 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.